Can Oral 311c90, a novel 5-ht1dagonist, prevent migraine headache when taken during an aura?

European Neurology

Volumn 36, Issue , 1996, Pages 28-31

  Dowson, Andrew ^a  

^a ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

Author keywords

311C90; Aura; Efficacy

Indexed keywords

SEROTONIN AGONIST; ZOLMITRIPTAN;

ADULT; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ELECTROCARDIOGRAPHY; FEMALE; HUMAN; MALE; MIGRAINE; NAUSEA; ORAL DRUG ADMINISTRATION; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TIME; UNITED KINGDOM; VERTIGO;

ADMINISTRATION, ORAL; ADULT; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; OXAZOLES; OXAZOLIDINONES; SEROTONIN AGONISTS; TRYPTAMINES;

EID: 0030010540     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000119101     Document Type: Article

References (9)

1. Goadsby PJ, Edvinsson L: Peripheral and central trigeminovascular activation in cat is inhibited by the novel serotonin (5-HTI-ID receptor agonist 311C90. Headache 1994;34:394-399.
2. Manin GR, Dixon RM: Preclinical and clinical pharmacology of the novel antimigraine compound. 31 1C90. Headache 1995:35:291.
3. Visscr WH, Fenari MD, Klein KB, Cox RC, Jones D: 311C90, a new central and peripherally acting 5-HT, receptor agonist in the acute oral treatment of migraine: A double-blind, placebo-controlled, dose range finding study. Neurology 1996:46:522-526.
4. Dahlof C, Diener HC, Goadsby PJ, Massiou H, et al: A multicenter, double-blind, placebo-controlled study to investigate the efficacy and safety of oral doses of 311C90 in the acute treatment of migraine. Headache 1995:35:292.
5. Headache Classification Committee of the International Headache Society: Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988:8(suppl 7): 19-28.
6. Rapoport AM, Cady RK, Mathew NT, et al (for the US 311C90 Dose Ranging Study Group): Optimizing the oral dose of 3I1C90 in the acute treatment of migraine. Cephalalgia 1995;15(suppl 14):221.
7. Earl NL: 31IC90. a new acute treatment for migraine: an overview of safety. Cephalalgia 1995; 15(suppl 14):217.
8. Bates D, Ashford E, Dawson R, et al (for the Sumatriptan Aura Study Group): Subcutaneous sumatriptan during the migraine aura. Neurology 1994:44:1587-1592.
9. Kaube H, Hoskin KL, Goadsby PJ: Sumatriptan inhibits central trigeminal neurons only after blood-brain barrier disruption. Br J Pharmacol 1993:109:788-792.